Cryoport spent the first half of 2026 shrinking a loss-making courier business and repositioning the rest of the company around the two parts that actually earn money. The strategic story of the period is not the income statement, which still posts a loss, but the June 2025 divestiture of the CRYOPDP specialty-courier arm to DHL Supply Chain for $133 million. That sale, now fully behind the company, removed the segment with the thinnest margins and the most working-capital drag. It left the balance sheet holding $269.3 million of cash against convertible notes that mature in December 2026. The entire investment case now turns on what that cash stack is doing in the run-up to the maturity, and on whether the remaining services and equipment businesses can grow fast enough to make the maturity a non-event rather than a forced-financing moment.
The operating evidence so far points in a favorable direction. Revenue in the second quarter rose 7.7% to $49.0 million, and the more important number is the mix. The higher-margin recurring storage line, BioStorage/BioServices, grew 24.8%. The company is now supporting 779 cell and gene therapy clinical trials worldwide, up 51 from a year earlier. Commercial cell and gene therapy revenue inside the services line jumped 26.5% to $9.4 million. Growth is concentrating in the exact segment where Cryoport has the most pricing power and the least competition, which is the part of the story the top line alone does not reveal.
The central debate is whether the market is pricing a business that has quietly turned a corner, or a business that is about to have to spend its war chest. At the current $15.81 per share, the company carries an enterprise value of roughly $637 million. That is about 3.3x annualized revenue. More tellingly, after the convertible notes are netted out, the position is net cash of about $4.16 per share. A meaningful slice of the current price is the treasury, not the operations. The falsifiable clock is the December 2026 maturity: if the company retires or refinances the notes from its own balance sheet without a dilutive equity raise, the treasury-value framing dissolves and the stock has room to re-rate toward an operating multiple. If the maturity forces a raise into a soft tape, the net-cash cushion shrinks and the overhang of roughly 16 million convertible and preferred shares comes to dominate the story. What would make the market wrong in either direction is the Q3 and Q4 print on BioStorage/BioServices growth and on adjusted EBITDA from continuing operations, which finally turned positive in the second quarter at $375,000 for the first time in the comparable periods presented.